secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001493152-24-023097
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Announces Results of 2024 Annual Meeting, Stockholders Approve Reverse Split Authorization
--------------------------------------------------------------------------------

- Re-elected directors Jessica D. Grossman, M.D. (28,626,331 for) and Susan L. Kelley, M.D. (28,623,481 for) as Class I directors.
- Ratified Haskell & White LLP as independent auditor for FY2024 with 53,420,221 votes for, 1,624,718 against.
- Advisory approval of named executive officer compensation received 26,182,433 votes for, 3,556,256 against, 594,264 abstentions.
- Approved reverse stock split authorization at ratio between 1-for-2 and 1-for-12, with 42,657,404 for, 10,792,335 against.
- Approved meeting adjournment proposal to solicit additional proxies if needed, with 44,780,743 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224023097/0001493152-24-023097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224023097/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-023097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer